Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an
increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been …

Fostamatinib, a recently approved Syk inhibitor used in adult primary immune
thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However …

Introduction. The phase 3 randomized, placebo-controlled trials of the SYK inhibitor
fostamatinib in adult patients with ITP were followed by an open-label extension (OLE) study …

Patients with immune thrombocytopenia (ITP) are at increased risk for bleeding and are
paradoxically at increased risk for thrombosis. Many patients with ITP have underlying …

Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune
thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as …

Background Immune thrombocytopenia (ITP) is an immune-mediated disease that results in
low platelet counts. Despite appropriate treatment, many patients continue to experience …

Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …

Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved for the treatment of
chronic primary immune thrombocytopenia (ITP) in the United States, Canada and some …

Introduction Immune thrombocytopenia (ITP), a disease that commonly presents with an
increased risk of bleeding, can also paradoxically produce an increased risk of …

Abstract Fostamatinib (Tavalisse®; Tavlesse®) is the first spleen tyrosine kinase (Syk)
inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP) in adult …